CN113226359B - 具有改进的表型特性的t细胞组合物 - Google Patents

具有改进的表型特性的t细胞组合物 Download PDF

Info

Publication number
CN113226359B
CN113226359B CN201980087076.3A CN201980087076A CN113226359B CN 113226359 B CN113226359 B CN 113226359B CN 201980087076 A CN201980087076 A CN 201980087076A CN 113226359 B CN113226359 B CN 113226359B
Authority
CN
China
Prior art keywords
cells
memory
cell
specific
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980087076.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226359A (zh
Inventor
马赛厄斯·厄可
克丽丝蒂·琼斯
金素贞
劳伦·苏亚雷斯
肯·卡特
斯科特·卡莫
丹·贝德纳里克
维尼塔·伊达瓦纳
艾米丽·卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neximmune Inc
Original Assignee
Neximmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neximmune Inc filed Critical Neximmune Inc
Priority to CN202410616338.3A priority Critical patent/CN118903396A/zh
Publication of CN113226359A publication Critical patent/CN113226359A/zh
Application granted granted Critical
Publication of CN113226359B publication Critical patent/CN113226359B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/4239—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980087076.3A 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物 Active CN113226359B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410616338.3A CN118903396A (zh) 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862757467P 2018-11-08 2018-11-08
US62/757,467 2018-11-08
US201962821031P 2019-03-20 2019-03-20
US62/821,031 2019-03-20
US201962867499P 2019-06-27 2019-06-27
US62/867,499 2019-06-27
PCT/US2019/060477 WO2020097466A1 (en) 2018-11-08 2019-11-08 T cell compositions with improved phenotypic properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410616338.3A Division CN118903396A (zh) 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物

Publications (2)

Publication Number Publication Date
CN113226359A CN113226359A (zh) 2021-08-06
CN113226359B true CN113226359B (zh) 2024-05-24

Family

ID=70612526

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980087076.3A Active CN113226359B (zh) 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物
CN202410616338.3A Pending CN118903396A (zh) 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410616338.3A Pending CN118903396A (zh) 2018-11-08 2019-11-08 具有改进的表型特性的t细胞组合物

Country Status (12)

Country Link
US (2) US20200188435A1 (https=)
EP (1) EP3876979A4 (https=)
JP (1) JP2022512948A (https=)
KR (1) KR20210095157A (https=)
CN (2) CN113226359B (https=)
AU (1) AU2019375997A1 (https=)
BR (1) BR112021008963A2 (https=)
CA (1) CA3118757A1 (https=)
IL (1) IL282914A (https=)
MX (1) MX2021005372A (https=)
SG (1) SG11202104611YA (https=)
WO (1) WO2020097466A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
JP7692633B2 (ja) * 2021-05-07 2025-06-16 康人 徳元 メモリーｔ細胞の製造方法
CN113388612A (zh) * 2021-06-18 2021-09-14 重庆天科雅生物科技有限公司 一种针对表位点为iyvlvmlvl的tcr所设计的引物及其应用
WO2024148216A2 (en) * 2023-01-05 2024-07-11 Neximmune, Inc. Combination therapy with t cell engager

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093464A1 (en) * 2015-12-04 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules
CN107002038A (zh) * 2014-09-17 2017-08-01 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
WO2017161092A1 (en) * 2016-03-16 2017-09-21 Neximmune, Inc. Production of antigen-specific t-cells
CN108472346A (zh) * 2015-11-05 2018-08-31 朱诺治疗学股份有限公司 含有traf诱导结构域的嵌合受体及相关组合物和方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
JP3680219B2 (ja) * 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DE60334474D1 (de) 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
PT1956080E (pt) 2005-08-08 2011-12-30 San Raffaele Centro Fond Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória
WO2009094273A2 (en) 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
WO2010065544A2 (en) 2008-12-01 2010-06-10 The Johns Hopkins University Diagnostic and treatment methods for cancer based on immune inhibitors
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US10463750B2 (en) 2013-02-15 2019-11-05 The Johns Hopkins University Antigen-Specific T cell redirectors
KR102164405B1 (ko) 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US11807675B2 (en) 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
WO2015127190A1 (en) * 2014-02-21 2015-08-27 Argos Therapeutics, Inc. Tscm cells and methods for use
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
HUE049514T2 (hu) 2014-04-25 2020-09-28 Bluebird Bio Inc Javított eljárások adoptív sejtterápiák kialakítására
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
IL258935B2 (en) 2015-10-28 2024-08-01 Life Tech As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
IT201700041430A1 (it) * 2017-04-13 2018-10-13 Sarong Spa Metodo e apparato per realizzare capsule con filtro
BR112020005552A2 (pt) * 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
EP3704229B1 (en) * 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002038A (zh) * 2014-09-17 2017-08-01 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
CN108472346A (zh) * 2015-11-05 2018-08-31 朱诺治疗学股份有限公司 含有traf诱导结构域的嵌合受体及相关组合物和方法
WO2017093464A1 (en) * 2015-12-04 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules
WO2017161092A1 (en) * 2016-03-16 2017-09-21 Neximmune, Inc. Production of antigen-specific t-cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors;Nicoletta Cieri et al.;Blood;20130124;第121卷(第4期);573–584 *

Also Published As

Publication number Publication date
US20200215115A1 (en) 2020-07-09
BR112021008963A2 (pt) 2021-09-14
EP3876979A1 (en) 2021-09-15
US11007222B2 (en) 2021-05-18
CA3118757A1 (en) 2020-05-14
SG11202104611YA (en) 2021-06-29
KR20210095157A (ko) 2021-07-30
WO2020097466A1 (en) 2020-05-14
CN118903396A (zh) 2024-11-08
MX2021005372A (es) 2021-09-14
AU2019375997A1 (en) 2021-06-03
IL282914A (en) 2021-06-30
EP3876979A4 (en) 2022-08-24
JP2022512948A (ja) 2022-02-07
US20200188435A1 (en) 2020-06-18
CN113226359A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
JP7204719B2 (ja) 抗原特異的ｔ細胞を同定、濃縮、及び／または増殖させるための試薬及び方法
US20230399613A1 (en) Cell compositions comprising antigen-specific t cells for adoptive therapy
CN113226359B (zh) 具有改进的表型特性的t细胞组合物
US20230332131A1 (en) Production of antigen-specific t-cells
WO2026035444A1 (en) Methods for identifying functional neoantigens and their use in cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant